Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 “All currently FDA-approved anti-VEGF therapies for retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback